Literature DB >> 32871789

Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.

Naohiro Okano1, Kiyomi Hana2, Daisuke Naruge3, Kirio Kawai3, Takaaki Kobayashi3, Fumio Nagashima3, Hitoshi Endou2, Junji Furuse3.   

Abstract

BACKGROUND/AIM: Amino acids are among the most important nutrients for supplying energy and building protein blocks in cancers. L-type amino acid transporter (LAT) 1 is known to play a critical role in cancer growth. We have completed the first-in-human phase I study using the LAT1-specific inhibitor JPH203. PATIENTS AND METHODS: We evaluated plasma free amino acids (PFAAs), body mass index (BMI), and efficacy of JPH203 in patients enrolled in the phase I study.
RESULTS: LAT1-substrate PFAAs and branched chain amino acids (BCAAs) were higher in patients with biliary tract cancer (BTC) than in those with other cancers. High inhibition of uptake of LAT1-substrate PFAAs was associated with survival. BMI of more than the median was associated with disease control and survival. BCAAs tended to be associated with BMI.
CONCLUSION: BCAAs and BMI are useful predictors of the efficacy of JPH203, which shows promising activity against BTC. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  JPH203; L-type amino acid transporter; amino acids; biliary tract cancer; body mass index

Mesh:

Substances:

Year:  2020        PMID: 32871789      PMCID: PMC7652516          DOI: 10.21873/invivo.12077

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  37 in total

1.  Positive correlation of expression of L-type amino-acid transporter 1 with colorectal tumor progression and prognosis: Higher expression in sporadic colorectal tumors compared with ulcerative colitis-associated neoplasia.

Authors:  Takeshi Sakata; Kiyomi Hana; Tetuo Mikami; Tutomu Yoshida; Hitoshi Endou; Isao Okayasu
Journal:  Pathol Res Pract       Date:  2020-04-18       Impact factor: 3.250

Review 2.  Role of amino acid transport and countertransport in nutrition and metabolism.

Authors:  H N Christensen
Journal:  Physiol Rev       Date:  1990-01       Impact factor: 37.312

3.  High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.

Authors:  Nobuyuki Yanagisawa; Masaaki Ichinoe; Tetuo Mikami; Norihiro Nakada; Kiyomi Hana; Wasaburo Koizumi; Hitoshi Endou; Isao Okayasu
Journal:  J Clin Pathol       Date:  2012-07-19       Impact factor: 3.411

4.  Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.

Authors:  Pattama Wiriyasermkul; Shushi Nagamori; Hideyuki Tominaga; Noboru Oriuchi; Kyoichi Kaira; Hidekazu Nakao; Takeru Kitashoji; Ryuichi Ohgaki; Hidekazu Tanaka; Hitoshi Endou; Keigo Endo; Hiroyuki Sakurai; Yoshikatsu Kanai
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

Review 5.  Amino acid transporters revisited: New views in health and disease.

Authors:  Palanivel Kandasamy; Gergely Gyimesi; Yoshikatsu Kanai; Matthias A Hediger
Journal:  Trends Biochem Sci       Date:  2018-08-31       Impact factor: 13.807

6.  High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.

Authors:  Masaaki Ichinoe; Tetuo Mikami; Tsutomu Yoshida; Ikuyo Igawa; Tomoko Tsuruta; Norihiro Nakada; Naohiko Anzai; Yoshiyuki Suzuki; Hitoshi Endou; Isao Okayasu
Journal:  Pathol Int       Date:  2011-03-17       Impact factor: 2.534

7.  Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system.

Authors:  K Tomiyoshi; K Amed; S Muhammad; T Higuchi; T Inoue; K Endo; D Yang
Journal:  Nucl Med Commun       Date:  1997-02       Impact factor: 1.690

8.  First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.

Authors:  Naohiro Okano; Daisuke Naruge; Kirio Kawai; Takaaki Kobayashi; Fumio Nagashima; Hitoshi Endou; Junji Furuse
Journal:  Invest New Drugs       Date:  2020-03-20       Impact factor: 3.850

9.  Perioperative dynamics and significance of plasma-free amino acid profiles in colorectal cancer.

Authors:  Kayoko Katayama; Akio Higuchi; Hiroshi Yamamoto; Atsuko Ikeda; Shinya Kikuchi; Manabu Shiozawa
Journal:  BMC Surg       Date:  2018-02-21       Impact factor: 2.102

10.  The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).

Authors:  Yann Cormerais; Pierre André Massard; Milica Vucetic; Sandy Giuliano; Eric Tambutté; Jerome Durivault; Valérie Vial; Hitoshi Endou; Michael F Wempe; Scott K Parks; Jacques Pouyssegur
Journal:  J Biol Chem       Date:  2018-01-11       Impact factor: 5.157

View more
  6 in total

Review 1.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

Review 2.  Immunometabolism - The Role of Branched-Chain Amino Acids.

Authors:  Berkay Yahsi; Gurcan Gunaydin
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 3.  Clinical development of metabolic inhibitors for oncology.

Authors:  Kathryn M Lemberg; Sadakatali S Gori; Takashi Tsukamoto; Rana Rais; Barbara S Slusher
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

Review 4.  Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways.

Authors:  Xue Zhao; Shinichi Sakamoto; Maihulan Maimaiti; Naohiko Anzai; Tomohiko Ichikawa
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

5.  The Nutraceutical Alliin From Garlic Is a Novel Substrate of the Essential Amino Acid Transporter LAT1 (SLC7A5).

Authors:  Raffaella Scanga; Mariafrancesca Scalise; Filomena Rovella; Teresa Maria Rosaria Regina; Michele Galluccio; Cesare Indiveri
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

6.  N-glycosylation is crucial for trafficking and stability of SLC3A2 (CD98).

Authors:  Lara Console; Mariafrancesca Scalise; Simona Salerno; Raffaella Scanga; Deborah Giudice; Loredana De Bartolo; Annamaria Tonazzi; Cesare Indiveri
Journal:  Sci Rep       Date:  2022-08-26       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.